Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
Adult
Age Factors
Aged
B-Lymphocytes
/ drug effects
Female
Humans
Immunosuppressive Agents
/ administration & dosage
Maintenance Chemotherapy
Male
Middle Aged
Nephrosis, Lipoid
/ diagnosis
Recurrence
Remission Induction
Retrospective Studies
Rituximab
/ administration & dosage
Time Factors
Treatment Outcome
B-cell depletion
Minimal change disease
Nephrotic syndrome
Relapse
Rituximab
Steroid
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
10
04
2020
accepted:
26
07
2020
pubmed:
8
8
2020
medline:
25
8
2021
entrez:
8
8
2020
Statut:
ppublish
Résumé
Rituximab (RTX) has been reported to effectively treat minimal change disease (MCD) in adults. However, the efficacy of RTX as maintenance therapy, especially in older patients, remains unclear. This study aimed to evaluate the efficacy of repeat-dose RTX maintenance therapy regardless of age. We retrospectively reviewed the clinical courses of 13 biopsy-proven adult MCD patients receiving RTX and evaluated the relapse rate, concomitant steroid and immunosuppressant use, relationship between B-cell depletion time and relapse, and adverse events. Mean patient age at start of RTX therapy was 51.5 ± 20.1 years. Each RTX induction consisted of a single 375 mg/m Repeat-dose RTX as maintenance therapy efficiently prevented recurrence and was well tolerated in adult MCD patients including older. This regimen has the potential to maintain prolonged remission. Future studies in larger cohorts are needed to identify the optimal dose and frequency and evaluate the long-term effectiveness and safety of this regimen.
Sections du résumé
BACKGROUND
BACKGROUND
Rituximab (RTX) has been reported to effectively treat minimal change disease (MCD) in adults. However, the efficacy of RTX as maintenance therapy, especially in older patients, remains unclear. This study aimed to evaluate the efficacy of repeat-dose RTX maintenance therapy regardless of age.
METHODS
METHODS
We retrospectively reviewed the clinical courses of 13 biopsy-proven adult MCD patients receiving RTX and evaluated the relapse rate, concomitant steroid and immunosuppressant use, relationship between B-cell depletion time and relapse, and adverse events.
RESULTS
RESULTS
Mean patient age at start of RTX therapy was 51.5 ± 20.1 years. Each RTX induction consisted of a single 375 mg/m
CONCLUSIONS
CONCLUSIONS
Repeat-dose RTX as maintenance therapy efficiently prevented recurrence and was well tolerated in adult MCD patients including older. This regimen has the potential to maintain prolonged remission. Future studies in larger cohorts are needed to identify the optimal dose and frequency and evaluate the long-term effectiveness and safety of this regimen.
Identifiants
pubmed: 32761467
doi: 10.1007/s10157-020-01943-3
pii: 10.1007/s10157-020-01943-3
doi:
Substances chimiques
Immunosuppressive Agents
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM